Spoken Alpha
ENDRA Life Sciences Inc.
ENDRA Life Sciences develops Thermo-Acoustic Enhanced Ultrasound (TAEUS), a medical imaging technology platform designed to assess liver fat content as a biomarker for metabolic diseases including fatty liver disease and metabolic dysfunction-associated steatohepatitis.
ENDRA Life Sciences Inc is a Healthcare company operating in Diagnostics & Research with a $8.4M market cap.
NDRA beat consensus EPS by 0.3% in Q2 FY2026, reported Aug 13, 2026.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NDRA.
$ curl https://api.spokenalpha.com/v1/companies/NDRAFAQ
Spoken Alpha indexes NDRA's earnings call transcripts at https://spokenalpha.com/companies/NDRA. Each call links to attributed speakers and parsed analyst Q&A. ENDRA Life Sciences Inc.'s own investor relations page is at https://investors.endrainc.com/.
ENDRA Life Sciences Inc. (NDRA) held its most recent earnings call on 2024-08-22, covering fiscal Q2 2024.
ENDRA Life Sciences Inc. (NDRA) operates in the Healthcare sector (Diagnostics & Research industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.63 | $-0.84 | +25.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-1.09 | $-1.23 | +11.4% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-2.23 | $-1.23 | -81.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-2.10 | $-1.95 | -7.7% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-1.71 | $-2.27 | +24.7% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-2.59 | $-3.91 | +33.8% | $211.6K | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $25.20 | $-4.10 | +100.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-14 | $-9.54 | $-62.30 | +84.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-140.00 | $-122.50 | -14.3% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-455.00 | $-472.50 | +3.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.05 | $-0.36 | +86.1% | $428.4K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-700.00 | $-752.50 | +7.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-752.50 | $-962.50 | +21.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-1627.50 | $-1828.75 | +11.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-13 | $-0.96 | $-0.90 | -6.7% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-1750.00 | $-1925.00 | +9.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-2100.00 | $-1925.00 | -9.1% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-2450.00 | $-2800.00 | +12.5% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-29 | $-1.60 | $-1.60 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-2100.00 | $-2800.00 | +25.0% | $0 | — | — | EODHD |
Source: EODHD. NDRA reported actuals as published; sparse fields render as —.